Alvocidib

Drug Profile

Alvocidib

Alternative Names: Alvocidib hydrochloride; Flavopiridol; HL-275; HMR 1275; IND 46211; L 868275; MDL-107826A; NSC 649890

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer National Cancer Institute (USA); Tolero Pharmaceuticals
  • Class Antineoplastics; Flavonoids; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Germ cell and embryonal neoplasms
  • Phase I B cell lymphoma
  • Preclinical Multiple myeloma; Myelodysplastic syndromes
  • No development reported Chronic lymphocytic leukaemia
  • Discontinued HIV infections; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 21 Jun 2017 Phase-II clinical trials in Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy or greater) in Europe (IV)
  • 05 Apr 2017 Preclinical trials in Multiple myeloma in USA (unspecified route) before April 2017
  • 05 Apr 2017 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Multiple myeloma presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top